Enanta Pharmaceuticals to Present Preclinical Data for EDP-721, its Novel Oral Hepatitis B Virus RNA Destabilizer, at the Int...
03 June 2021 - 9:00PM
Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage
biotechnology company dedicated to creating small molecule drugs
for viral infections and liver diseases, today announced that the
company will have a poster presentation showcasing preclinical data
for EDP-721, a novel, potent and selective oral HBV RNA
destabilizer being developed for use in an all-oral functional cure
of hepatitis B virus, at the upcoming European Association for the
Study of the Liver’s (EASL) International Liver Congress 2021,
being held virtually June 23-26, 2021.
Details of the poster presentation are as follows: Date/Time:
June 23, 2021, 08:00 CET Poster 942: Discovery and characterization
of EDP-721, a novel hepatitis B virus RNA destabilizer Session
Name: Viral Hepatitis B/D: Therapy Presenter: Michael Vaine, Ph.D.,
United States
About Enanta
Enanta is using its robust, chemistry-driven approach and drug
discovery capabilities to become a leader in the discovery and
development of small molecule drugs for the treatment of viral
infections and liver diseases. Enanta’s research and development
efforts have produced clinical candidates for the following disease
targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV)
and non-alcoholic steatohepatitis (NASH). Enanta is also conducting
research in SARS-CoV-2 (COVID-19) and human metapneumovirus
(hMPV).
Enanta’s research and development activities are funded by
royalties from hepatitis C virus (HCV) products developed under its
collaboration with AbbVie. Glecaprevir, a protease inhibitor
discovered by Enanta, is sold by AbbVie in numerous countries as
part of its leading treatment for chronic HCV infection under the
tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.)
(glecaprevir/pibrentasvir). Please visit www.enanta.com for more
information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210603005272/en/
Media and Investor Contact Jennifer Viera 617-744-3848
jviera@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Mar 2024 to May 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From May 2023 to May 2024
